Skip to content

Study · Not a test of the peptide alone · 2018

6 results

The cost-effectiveness of dulaglutide versus insulin glargine for the treatment of type 2 diabetes mellitus in Japan.

Ishii H, Madin-Warburton M, Strizek A, Thornton-Jones L, Suzuki S

Journal of medical economics7 Feb 2018Cited by 12 (Europe PMC)

PMID29357718 (opens in a new tab)DOI10.1080/13696998.2018.1431918 (opens in a new tab)PepBankPUB-29357718
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

  1. 01Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther

    In a Japanese T2DM simulation, dulaglutide produced more quality-adjusted life years than insulin glargine.

    In plain wordsA computer model predicted more years adjusted for quality of life with dulaglutide than insulin glargine in Japanese T2DM.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseQuality-adjusted life years
    Study

    n: not reported in source

    IQVIA CORE Diabetes Model
    Comparator
    Insulin glargine
    Outcome group
    Healthcare costs and utilization · Whole body

    Source sentences

    Summary
    Dulaglutide 0.75 mg was associated with higher quality-adjusted life years (QALYs), life years (LYs), and total costs, compared to insulin glargine, resulting in an incremental cost-effectiveness ratio (ICER) of 416,280 JPY/QALY gained.
    2 context sentences
    Summary · context
    The IQVIA CORE Diabetes Model (version 9) was used to estimate the long-term costs and effects of treatment with dulaglutide and insulin glargine.
    Summary · context
    Direct comparative data from the Araki 2015 trial (NCT01584232) was used to inform the analysis.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  2. 02Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther

    In a Japanese T2DM simulation, dulaglutide produced more life years than insulin glargine.

    In plain wordsA computer model predicted longer survival with dulaglutide than insulin glargine in Japanese T2DM.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseLife years
    Study

    n: not reported in source

    IQVIA CORE Diabetes Model
    Comparator
    Insulin glargine
    Outcome group
    Healthcare costs and utilization · Whole body

    Source sentences

    Summary
    Dulaglutide 0.75 mg was associated with higher quality-adjusted life years (QALYs), life years (LYs), and total costs, compared to insulin glargine, resulting in an incremental cost-effectiveness ratio (ICER) of 416,280 JPY/QALY gained.
    2 context sentences
    Summary · context
    The IQVIA CORE Diabetes Model (version 9) was used to estimate the long-term costs and effects of treatment with dulaglutide and insulin glargine.
    Summary · context
    Direct comparative data from the Araki 2015 trial (NCT01584232) was used to inform the analysis.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  3. 03Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther

    In a Japanese T2DM simulation, dulaglutide produced higher total costs than insulin glargine.

    In plain wordsA computer model predicted higher total costs with dulaglutide than insulin glargine in Japanese T2DM.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseTotal costs
    Study

    n: not reported in source

    IQVIA CORE Diabetes Model
    Comparator
    Insulin glargine
    Outcome group
    Healthcare costs and utilization · Whole body

    Source sentences

    Summary
    Dulaglutide 0.75 mg was associated with higher quality-adjusted life years (QALYs), life years (LYs), and total costs, compared to insulin glargine, resulting in an incremental cost-effectiveness ratio (ICER) of 416,280 JPY/QALY gained.
    2 context sentences
    Summary · context
    The IQVIA CORE Diabetes Model (version 9) was used to estimate the long-term costs and effects of treatment with dulaglutide and insulin glargine.
    Summary · context
    Direct comparative data from the Araki 2015 trial (NCT01584232) was used to inform the analysis.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  4. 04Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther

    In a Japanese T2DM simulation, dulaglutide versus insulin glargine had an ICER of 416,280 JPY/QALY gained.

    In plain wordsA computer model predicted an extra cost of 416,280 JPY per quality-adjusted life year with dulaglutide versus insulin glargine.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableIncremental cost-effectiveness ratio
    Study

    n: not reported in source

    IQVIA CORE Diabetes Model
    Comparator
    Insulin glargine
    Outcome group
    Healthcare costs and utilization · Whole body

    Measurements

    ICER
    416,280 JPY/QALY
    dulaglutide versus insulin glargine

    Source sentences

    Summary
    Dulaglutide 0.75 mg was associated with higher quality-adjusted life years (QALYs), life years (LYs), and total costs, compared to insulin glargine, resulting in an incremental cost-effectiveness ratio (ICER) of 416,280 JPY/QALY gained.
    2 context sentences
    Summary · context
    The IQVIA CORE Diabetes Model (version 9) was used to estimate the long-term costs and effects of treatment with dulaglutide and insulin glargine.
    Summary · context
    Direct comparative data from the Araki 2015 trial (NCT01584232) was used to inform the analysis.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  5. 05Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther

    In a Japanese T2DM simulation, dulaglutide increased time alive without diabetes complications by 4 months versus insulin glargine.

    In plain wordsA computer model predicted 4 more months alive without diabetes complications with dulaglutide than insulin glargine in Japanese T2DM.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseTime alive without diabetes complications
    Study

    n: not reported in source

    IQVIA CORE Diabetes Model
    Comparator
    Insulin glargine
    Outcome group
    Healthcare costs and utilization · Whole body

    Measurements

    Additional complication-free survival
    4 months
    dulaglutide versus insulin glargine

    Source sentences

    Summary
    Treatment with dulaglutide increased the time alive and free from diabetes-related complications by 4 months.
    2 context sentences
    Summary · context
    The IQVIA CORE Diabetes Model (version 9) was used to estimate the long-term costs and effects of treatment with dulaglutide and insulin glargine.
    Summary · context
    Direct comparative data from the Araki 2015 trial (NCT01584232) was used to inform the analysis.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  6. 06Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther

    In a Japanese T2DM simulation, dulaglutide versus insulin glargine results were robust to plausible input and modeling assumption changes.

    In plain wordsThe Japanese T2DM model comparison of dulaglutide and insulin glargine remained robust when plausible inputs and assumptions changed.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableSensitivity analysis robustness
    Study

    n: not reported in source

    IQVIA CORE Diabetes Model
    Comparator
    Insulin glargine
    Outcome group
    Healthcare costs and utilization · Whole body

    Source sentences

    Summary
    OWSA and PSA indicated that results were robust to plausible variations in input parameters and modeling assumptions.
    2 context sentences
    Summary · context
    The IQVIA CORE Diabetes Model (version 9) was used to estimate the long-term costs and effects of treatment with dulaglutide and insulin glargine.
    Summary · context
    Direct comparative data from the Araki 2015 trial (NCT01584232) was used to inform the analysis.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.